オーファンドラッグ(希少疾患治療薬)の世界市場2019-2023

調査会社Technavio社が発行したリサーチレポート(データ管理コード:IRTNTR31893)
◆英語タイトル:Orphan Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023
◆発行会社/調査会社:Technavio
◆商品コード:IRTNTR31893
◆発行日:2019年8月26日
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、北米、その他
◆産業分野:医療
◆ページ数:172
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール(受注後24時間以内)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥342,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥456,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Technavio社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[オーファンドラッグ(希少疾患治療薬)の世界市場2019-2023]についてメールでお問い合わせはこちら
Technavio社の本調査レポートでは、オーファンドラッグ(希少疾患治療薬)の世界市場について調べ、オーファンドラッグ(希少疾患治療薬)の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、オーファンドラッグ(希少疾患治療薬)の市場規模をセグメンテーション別(製品別(生物製剤、非生物学的製剤)、)と地域別(グローバル、アジア太平洋、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社はオーファンドラッグ(希少疾患治療薬)の世界市場規模が2019-2023期間中に年平均12%成長すると予測しています。
・サマリー
・レポートの範囲
・オーファンドラッグ(希少疾患治療薬)の市場状況
・オーファンドラッグ(希少疾患治療薬)の市場規模
・オーファンドラッグ(希少疾患治療薬)の市場予測
・オーファンドラッグ(希少疾患治療薬)の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(生物製剤、非生物学的製剤)
・オーファンドラッグ(希少疾患治療薬)の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
*** レポート概要(サマリー)***

Global Orphan Drugs Market: About this market
Technavio’s orphan drugs market analysis considers sales from both biologics and non-biologics. Our analysis also considers the sales of orphan drugs in Asia, Europe, North America, and ROW. In 2018, the biologics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high efficacy will play a significant role in the biologics segment to maintain its market position. Also, our global orphan drugs market report looks at factors such as robust pipeline and recent drug approvals, rising incidence of the rare disease, availability of incentives for orphan drug development. However, uncertainties in the delay in diagnosis, risks associated with the clinical development of novel orphan drugs and challenges associated with pricing and reimbursements for orphan drugs may hamper the growth of the orphan drugs industry over the forecast period.

Global Orphan Drugs Market: Overview

Rising incidence of rare diseases
Orphan drugs are specifically used to treat rare diseases, and the prevalence of such health conditions has a direct influence on the sales of orphan drugs. Rare diseases include inherited genetic disorders, rare types of cancer, tropical infectious diseases, and neurodegenerative diseases. The prevalence and distribution of rare diseases are skewed. Although some rare diseases are inherited, others are a product of harmful environmental factors. This will lead to the expansion of the global orphan drugs market at a CAGR of almost 12% during the forecast period.

The emergence of combination therapies and novel targets
The potential advances in several areas such as immunotherapies and CGT are rekindling interest and enabling progress in the development of orphan drugs. These advances have been made in target selection, and combination therapy approaches for effectively reversing the immunosuppressive mechanisms, thereby enhancing the durability of the therapeutics. This development is expected to have a positive impact on the overall market growth.
For the detailed list of factors that will drive the global orphan drugs market during the forecast period 2019-2023, click here.

Competitive Landscape
With the presence of several major players, the global orphan drugs market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading orphan drugs manufacturers, that include Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, Takeda Pharmaceutical Co. Ltd.

Also, the orphan drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

*** レポート目次(コンテンツ)***

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Biologics – Market size and forecast 2018-2023
• Non-biologics – Market size and forecast 2018-2023
• Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
• PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 12: MARKET TRENDS
• Strategic focus on alliances, partnerships, and M&A
• Emergence of combination therapies and novel targets
• Rising demand for genetic tests and protein biomarkers
PART 13: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 14: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bristol-Myers Squibb Co.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson Services Inc.
• Novartis AG
• Takeda Pharmaceutical Co. Ltd.
PART 15: APPENDIX
• Research methodology
• List of abbreviations
• Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO

Exhibit 01: Recent mega-mergers in pharmaceuticals
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ billions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Some of the first-in-class orphan drugs approved by the US FDA during 2017-2018
Exhibit 11: Five forces analysis 2018
Exhibit 12: Five forces analysis 2023
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Market condition – Five forces 2018
Exhibit 19: Some of the late-stage orphan drugs
Exhibit 20: Product – Market share 2018-2023 (%)
Exhibit 21: Comparison by product
Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ billions)
Exhibit 23: Number of new or expanded indications approved for novel orphan biologics to the number of rare and non-rare diseases from the US FDA January 2013-June 2019
Exhibit 24: Promising regenerative orphan drugs pricing plans
Exhibit 25: Biologics – Year-over-year growth 2019-2023 (%)
Exhibit 26: Non-biologics – Market size and forecast 2018-2023 ($ billions)
Exhibit 27: Non-biologics – Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by product
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America – Market size and forecast 2018-2023 ($ billions)
Exhibit 33: Number of orphan drug approvals in US 2014-2018
Exhibit 34: US FDA orphan drug marketing approvals in major therapeutic areas 2008-2017
Exhibit 35: List of expensive orphan drugs launched in US
Exhibit 36: Leading vendors and their product sales in US 2018.
Exhibit 37: Status of BTD, PR, and ODD for novel drugs 2013-2017
Exhibit 38: RMAT designation requests by product type 2018
Exhibit 39: North America – Year-over-year growth 2019-2023 (%)
Exhibit 40: Europe – Market size and forecast 2018-2023 ($ billions)
Exhibit 41: Orphan drug approvals in Europe during 2010-2018
Exhibit 42: Applications for ODD in EU 2005-2018
Exhibit 43: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 44: Asia – Market size and forecast 2018-2023 ($ billions)
Exhibit 45: Orphan drugs eligible for reimbursable under China’s state health insurance schemes
Exhibit 46: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 47: ROW – Market size and forecast 2018-2023 ($ billions)
Exhibit 48: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 49: Key leading countries
Exhibit 50: Market opportunity
Exhibit 51: List of promising drugs approved in US, Japan, and EU 2017-2019
Exhibit 52: Number of orphan drugs approved in US, EU, and Japan 2017 and 2018
Exhibit 53: Percentage of orphan and non-orphan drugs approved by the US FDA 2018
Exhibit 54: Incidence rate of rare diseases per year in US
Exhibit 55: Prevalence of rare diseases 2018 (millions)
Exhibit 56: Orphan drugs regulatory framework and incentives in key leading regions or countries
Exhibit 57: Impact of drivers and challenges
Exhibit 58: Several major M&A in the market
Exhibit 59: Expansion of combination therapies research areas of ICI approved drugs
Exhibit 60: Ongoing immunotherapy combinations studies with co-inhibitory molecules
Exhibit 61: Ongoing immunotherapy combinations studies with co-stimulatory molecules
Exhibit 62: Vendor landscape
Exhibit 63: Landscape disruption
Exhibit 64: Vendors covered
Exhibit 65: Vendor classification
Exhibit 66: Market positioning of vendors
Exhibit 67: Bristol-Myers Squibb Co. – Vendor overview
Exhibit 68: Bristol-Myers Squibb Co. – Business segments
Exhibit 69: Bristol-Myers Squibb Co. – Organizational developments
Exhibit 70: Bristol-Myers Squibb Co. – Geographic focus
Exhibit 71: Bristol-Myers Squibb Co. – Key offerings
Exhibit 72: Bristol-Myers Squibb Co. – Key customers
Exhibit 73: F. Hoffmann-La Roche Ltd. – Vendor overview
Exhibit 74: F. Hoffmann-La Roche Ltd. – Business segments
Exhibit 75: F. Hoffmann-La Roche Ltd. – Organizational developments
Exhibit 76: F. Hoffmann-La Roche Ltd. – Geographic focus
Exhibit 77: F. Hoffmann-La Roche Ltd. – Segment focus
Exhibit 78: F. Hoffmann-La Roche Ltd. – Key offerings
Exhibit 79: F. Hoffmann-La Roche Ltd. – Key customers
Exhibit 80: Johnson & Johnson Services Inc. – Vendor overview
Exhibit 81: Johnson & Johnson Services Inc. – Business segments
Exhibit 82: Johnson & Johnson Services Inc. – Organizational developments
Exhibit 83: Johnson & Johnson Services Inc. – Geographic focus
Exhibit 84: Johnson & Johnson Services Inc. – Segment focus
Exhibit 85: Johnson & Johnson Services Inc. – Key offerings
Exhibit 86: Johnson & Johnson Services Inc. – Key customers
Exhibit 87: Novartis AG – Vendor overview
Exhibit 88: Novartis AG – Business segments
Exhibit 89: Novartis AG – Organizational developments
Exhibit 90: Novartis AG – Geographic focus
Exhibit 91: Novartis AG – Segment focus
Exhibit 92: Novartis AG – Key offerings
Exhibit 93: Novartis AG – Key customers
Exhibit 94: Takeda Pharmaceutical Co. Ltd. – Vendor overview
Exhibit 95: Takeda Pharmaceutical Co. Ltd. – Business segments
Exhibit 96: Takeda Pharmaceutical Co. Ltd. – Organizational developments
Exhibit 97: Takeda Pharmaceutical Co. Ltd. – Geographic focus
Exhibit 98: Takeda Pharmaceutical Co. Ltd. – Key offerings
Exhibit 99: Takeda Pharmaceutical Co. Ltd. – Key customers
Exhibit 100: Validation techniques employed for market sizing
Exhibit 101: Definition of market positioning of vendors



*** 掲載企業 ***

Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Novartis AG, and Takeda Pharmaceutical Co. Ltd.

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
  • 米国の農業機械市場
    About Agricultural Machinery Agricultural machinery is used to optimize and add precision to agriculture practices at a large scale. The agricultural machinery market in the US comprises machinery and equipment used for performing agriculture practices. The global agricultural machinery market is ex …
  • 世界のセラミックフィルターエレメント市場2017
    Ceramic Filters Element Market Report by Material, Application, and Geography – Global Forecast to 2021 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United …
  • 非炭酸飲料の世界市場2017-2021
    About Still DrinksStill drinks are non-alcoholic beverages that are manufactured without any carbonation. These drinks do not contain any fizziness. With growing concerns regarding health issues, many consumers are shifting from alcoholic beverages to non-alcoholic beverages, like alcohol, when cons …
  • ピーナッツオイルの世界市場予測・分析:流通チャンネル別・地域別
    Global Peanut Oil Market: About this market Peanut oil is used in cooking and considered as a key ingredient in the beauty and personal care (BPC) and pharmaceutical sectors because of its nutritional value and health benefits. Technavio’s peanut oil analysis considers sales from the distribution ch …
  • ペントバルビタールの世界及び中国市場 2018年
    The 'Global and Chinese Pentobarbital Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Pentobarbital industry with a focus on the Chinese market. The report provides key statistics on the market status of the Pentobarbital manufactur …
  • 世界及び中国のテルペンチン市場2018
    The 'Global and Chinese Turpentine Industry, 2013-2023 Market Research Report' is a professional and in-depth study on the current state of the global Turpentine industry with a focus on the Chinese market. The report provides key statistics on the market status of the Turpentine manufacturers and i …
  • パーソナルケア用ワイプの世界市場:成長・動向・予測(2020年-2025年)
    The Global Personal Care Wipes Market is projected to grow at a CAGR of 5.4% during the forecast period (2020-2025). - The attractive packaging of personal care products and innovation in product material and fragrances are influencing the sales of personal care wipes across the globe. The growing u …
  • プラズマ溶接ロボットの世界市場2018-2022:自動車、金属、電子・半導体、その他
    This industry research report presents a comprehensive analysis of the plasma welding robots market by end-user (automotive industry, metal industry, electronics and semiconductor industry, and others), by application, and by geography (the Americas, APAC, and EMEA). The report also provides an anal …
  • 世界のヘキサブロモシクドデカン市場2017
    Notes:Sales, means the sales volume of Hexabromocyclododecane Revenue, means the sales value of Hexabromocyclododecane This report studies sales (consumption) of Hexabromocyclododecane in Global market, especially in United States, China, Europe and Japan, focuses on top players in these regions/cou …
  • 世界及び中国のオクタン市場2017
    The 'Global and Chinese Octane Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Octane industry with a focus on the Chinese market. The report provides key statistics on the market status of the Octane manufacturers and is a valuable …
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(IRTNTR31893 )"オーファンドラッグ(希少疾患治療薬)の世界市場2019-2023" (英文:Orphan Drugs Market by Product and Geography - Global Forecast and Analysis 2019-2023)はTechnavio社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。